ANI Pharmaceuticals, Inc.

generics, branded rare-disease and established-brand pharmaceuticals

ANIP · Nasdaq · United States

Share price · ANIP

$71.47-5.40 (-7.02%) 3M

close as of 2026-11-18 · 24h delayed · vol 314K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANIP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+5.1%
  2. 23 Sep 2026-4.5%
  3. 21 Aug 2026-2.5%

    Nothing announced by ANIP that day or the session before.

  4. 10 Aug 2026-3.2%
  5. 7 Aug 2026-5.3%
  6. 6 Aug 2026+3.4%
  7. 17 Jul 2026-3.3%
  8. 27 Feb 2026-4.2%
  9. 23 Feb 2026-3.4%
  10. 11 Feb 2026-4.6%

Share of unusual movement by asset

For each asset, the share of ANIP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—55%

No dated announcements about its assets since 2 Jul 2024.

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
AromataseSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
Glucocorticoid receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Beta-1/beta-2 adrenergic receptorsSmall molecule
HypertensionMigraineHypertrophic Cardiomyopathy
Approved
Beta-2 adrenergic receptor (ADRB2)Small molecule
Asthma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
AnastrozolePhase 3Advanced Breast Cancer
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$291M$13M$421M—$84M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$266M$15M$360M—$57M operating cash flowreport ↗
2026-Q1$237M$11M$311M—$58M operating cash flowreport ↗
2025-Q3$228M$12M$263M—$44M operating cash flowreport ↗
2025-Q2$211M$17M$218M—$76M operating cash flowreport ↗
2025-Q1$197M$11M$150M—$35M operating cash flowreport ↗
2024-Q3$148M$10M$145M$24M$12M operating cash flowreport ↗
2024-Q2$138M$7.3M$240M$2.3M$17M operating cash flowreport ↗
2024-Q1$137M$11M$229M—$18M operating cash flowreport ↗
2023-Q3$132M$11M$193M—$32M operating cash flowreport ↗
2023-Q2$117M$7.4M$162M—$21M operating cash flowreport ↗
2023-Q1$107M$5.9M$68M—$21M operating cash flowreport ↗
2022-Q3$84M$7.7M$61M$8.6M$3.6M operating cash flowreport ↗
2022-Q2$74M$4.2M$68M$15M-$11M operating cash flowreport ↗
2022-Q1$64M$5.3M$82M$20M-$19M operating cash flowreport ↗
2021-Q3$52M$2.5M$20M$4.5M-$5.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$883M$52M$286M—$185M operating cash flowreport ↗

ANI Pharmaceuticals reported revenue of $883.37M, up 43.8% YoY, with R&D spend of $51.66M, up 15.9% YoY. Cash and equivalents stood at $285.62M, and the company reported net income of $78.34M for fiscal 2025.

The company expects its pipeline to yield approximately 10 to 15 new product launches per year. During 2025, the FDA approved an expanded ILUVIEN label for chronic non-infectious uveitis affecting the posterior segment of the eye and a prefilled syringe format for Cortrophin Gel, and the company transitioned U.S. promotional efforts from YUTIQ to ILUVIEN. ANI also plans to build a dedicated sales organization during 2026 focused on acute gouty arthritis flares for Cortrophin Gel.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$614M$45M$145M$4.6M$64M operating cash flowreport ↗
2023-FY$487M$34M$221M—$119M operating cash flowreport ↗
2022-FY$316M$22M$53M$12M-$31M operating cash flowreport ↗
2021-FY$216M$11M$105M$11M$3.3M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 49 sales ($14.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Lalwani Nikhil · director, PRESIDENT & CEOOpen-market sale4,082$71.16$290KForm 4
2026-11-16Lalwani Nikhil · director, PRESIDENT & CEOOpen-market sale1,318$71.40$94KForm 4
2026-11-13Cook Meredith · SR. VP, GENERAL COUNSEL & SEC.Open-market sale500$70.80$35KForm 4
2026-10-29CAREY STEPHEN P. · SVP & CFOOpen-market sale2,850$72.87$208KForm 4
2026-10-15Lalwani Nikhil · director, PRESIDENT & CEOOpen-market sale5,400$71.89$388KForm 4
2026-10-13Cook Meredith · SR. VP, GENERAL COUNSEL & SEC.Open-market sale500$73.59$37KForm 4
2026-09-29CAREY STEPHEN P. · SVP & CFOOpen-market sale2,850$73.00$208KForm 4
2026-09-15Lalwani Nikhil · director, PRESIDENT & CEOOpen-market sale5,400$71.00$383KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 277 reporting institutions held 23.3M shares ($1.8B).

#InstitutionSharesValue
1BlackRock, Inc.2,747,492$211.3M
2VANGUARD CAPITAL MANAGEMENT LLC823,064$63.3M
3Soleus Capital Management, L.P.820,243$63.1M
4STATE STREET CORP771,587$59.3M
5TANG CAPITAL MANAGEMENT LLC707,500$54.4M
6GOLDENTREE ASSET MANAGEMENT LP667,981$51.3M
7Deep Track Capital, LP600,000$46.1M
8MILLENNIUM MANAGEMENT LLC592,013$45.5M
9ARROWSTREET CAPITAL, LIMITED PARTNERSHIP564,360$43.4M
10DIMENSIONAL FUND ADVISORS LP531,190$40.8M
11UBS Group AG497,702$38.3M
12GEODE CAPITAL MANAGEMENT, LLC489,201$37.6M
13Nuveen, LLC402,357$30.9M
14VANGUARD PORTFOLIO MANAGEMENT LLC375,965$28.9M
15Global Alpha Capital Management Ltd.361,240$27.8M